[go: up one dir, main page]

WO2014031586A3 - Methods for treating cardiovascular diseases - Google Patents

Methods for treating cardiovascular diseases Download PDF

Info

Publication number
WO2014031586A3
WO2014031586A3 PCT/US2013/055697 US2013055697W WO2014031586A3 WO 2014031586 A3 WO2014031586 A3 WO 2014031586A3 US 2013055697 W US2013055697 W US 2013055697W WO 2014031586 A3 WO2014031586 A3 WO 2014031586A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
subject
adipose tissue
lipoxygenase
flap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/055697
Other languages
French (fr)
Other versions
WO2014031586A2 (en
Inventor
Naser Ahmadi
Matthew BUDOFF
Raymond Tabibiazar
Fred CRAVES
Tilmann Brotz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tallikut Pharmaceuticals Inc
Original Assignee
Tallikut Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tallikut Pharmaceuticals Inc filed Critical Tallikut Pharmaceuticals Inc
Publication of WO2014031586A2 publication Critical patent/WO2014031586A2/en
Anticipated expiration legal-status Critical
Publication of WO2014031586A3 publication Critical patent/WO2014031586A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is based in part on the discovery that an inhibitor of the 5-lipoxygenase pathway (for example, a 5-lipoxygenase inhibitor or a 5-lipoxygenaseactivating protein (FLAP) inhibitor) can preserve and improve cardiac function, mitigate cardiac dysfunction, as well as reduce epicardial adipose tissue and/or pericardial adipose tissue in a subject suffering from a cardiovascular disease. Accordingly, the present invention provides methods for mitigating cardiac dysfunction in a subject in need thereof by administering to the subject a composition comprising a 5-lipoxygenase inhibitor or a FLAP inhibitor. The present invention further provides methods for preserving and/or improving cardiac function in a subject in need thereof by administering to the subject a composition comprising a 5-lipoxygenase inhibitor or a FLAP inhibitor. In addition, the present invention provides methods for reducing epicardial adipose tissue and/or pericardial adipose tissue in a subject in need thereof by administering to the subject a composition comprising a 5-lipoxygenase inhibitor or a FLAP inhibitor.
PCT/US2013/055697 2012-08-20 2013-08-20 Methods for treating cardiovascular diseases Ceased WO2014031586A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261691064P 2012-08-20 2012-08-20
US61/691,064 2012-08-20

Publications (2)

Publication Number Publication Date
WO2014031586A2 WO2014031586A2 (en) 2014-02-27
WO2014031586A3 true WO2014031586A3 (en) 2015-07-16

Family

ID=50150472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/055697 Ceased WO2014031586A2 (en) 2012-08-20 2013-08-20 Methods for treating cardiovascular diseases

Country Status (1)

Country Link
WO (1) WO2014031586A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1220451A1 (en) 2013-03-15 2017-05-05 Bioelectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
CN105078957B (en) * 2014-05-04 2017-11-21 中国医学科学院基础医学研究所 Trihydroxyflavone is preparing the purposes in being used to treat or prevent the medicine of abdominal aneurvsm
EP3677259A1 (en) * 2019-01-07 2020-07-08 Mosaiques Diagnostics And Therapeutics AG Use of arachidonyl trifluoromethyl ketone
CN115216528B (en) * 2022-06-02 2025-08-08 海南医学院 Application of RhoE gene in the preparation of medicines for treating diabetic cardiomyopathy

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035741A2 (en) * 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
US20060004040A1 (en) * 2002-08-26 2006-01-05 Jilly Evans Method for the prevention and/or treatment of atherosclerosis
WO2007056021A2 (en) * 2005-11-04 2007-05-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
WO2008067566A1 (en) * 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
WO2009002746A1 (en) * 2007-06-22 2008-12-31 Decode Genetics Ehf. Dosing schedules of leukotriene synthesis inhibitors for human therapy
US20090227638A1 (en) * 2005-03-23 2009-09-10 Marc Blouin Novel Pharmaceutical Compounds
US20090291981A1 (en) * 2008-05-23 2009-11-26 Amira Pharmaceuticals, Inc. 5-Lipoxygenase-Activating Protein Inhibitor
US20100075934A1 (en) * 2007-10-26 2010-03-25 Amira Pharmaceuticals, Inc. 5-lipoxygenase activating protein (flap) inhibitor

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004040A1 (en) * 2002-08-26 2006-01-05 Jilly Evans Method for the prevention and/or treatment of atherosclerosis
WO2004035741A2 (en) * 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
US20090227638A1 (en) * 2005-03-23 2009-09-10 Marc Blouin Novel Pharmaceutical Compounds
WO2007056021A2 (en) * 2005-11-04 2007-05-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
WO2008067566A1 (en) * 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
WO2009002746A1 (en) * 2007-06-22 2008-12-31 Decode Genetics Ehf. Dosing schedules of leukotriene synthesis inhibitors for human therapy
US20100075934A1 (en) * 2007-10-26 2010-03-25 Amira Pharmaceuticals, Inc. 5-lipoxygenase activating protein (flap) inhibitor
US20090291981A1 (en) * 2008-05-23 2009-11-26 Amira Pharmaceuticals, Inc. 5-Lipoxygenase-Activating Protein Inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALLEN, S ET AL.: "Differential Leukotriene Constrictor Responses in Human Atherosclerotic Coronary Arteries.", CIRCULATION., vol. 97, 23 June 1998 (1998-06-23), pages 2406 - 2413 *

Also Published As

Publication number Publication date
WO2014031586A2 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
WO2011057249A3 (en) Treatment of heart disease
BR112015012781A2 (en) composition comprising biological control agents
WO2011057251A3 (en) Treatment of heart disease
WO2012072713A3 (en) Lysine demethylase inhibitors such as cyclylcyclopropanamine derivatives for use in the treatment of diseases and disorders associated with flaviviridae
EA201290540A1 (en) TREATMENT OF HEART DISEASES
WO2013049770A3 (en) Methods of treating cancer
CA2871471C (en) Dna-pk inhibitors
NI201500128A (en) 3- PYRIMIDIN-4-IL-OXAZOLIDIN-2-ONAS AS INHIBITORS OF MUTANT HDI
PH12013500081B1 (en) Aqueous composition comprising bromhexine
EA201590368A1 (en) THE SYNERGY FUNCTIONAL COMPOSITION
WO2015095354A3 (en) Compositions and methods for treating fatty tissue buildup
WO2014031586A3 (en) Methods for treating cardiovascular diseases
WO2015076717A3 (en) Mscs in the treatment of cardiac disorders
BR112015029926A2 (en) combination of active agents for skin aging treatment
SG10201909382UA (en) Glyt1 inhibitors for use in the treatment of hematological disorders
WO2020227689A8 (en) Oligosaccharide compositions and methods of use
PH12017550090A1 (en) Composition for improving or preventing nonalcoholic fatty liver
BR112015022044A2 (en) a method of providing ocular neutroprotection
EA201590522A1 (en) METHODS OF INTRODUCTION OF RIFAXIMINE TO REDUCE WEIGHT AND TREAT OBESITY
WO2012045974A3 (en) Cosmetic use of a tropaeolum majus extract as an active principle for promoting the oxygenation of skin tissue
WO2015074010A3 (en) Compositions and methods for cardiac regeneration
WO2014201034A3 (en) Treatment for polyomavirus infection
PH12017550132A1 (en) Beta-casein a2 and antioxidant capacity
WO2013046059A3 (en) Methods and compositions for tamarind-based ocular disease treatment in combination with trehalose
WO2013058632A3 (en) Composition containing ohioensins f as a polytrichastrum alpinum-derived novel compound for preventing or treating arteriosclerosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13831464

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13831464

Country of ref document: EP

Kind code of ref document: A2